Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Xifaxan prior authorization?
Payers require PA for Xifaxan because of three factors: the drug’s high cost (over $2,200 retail per prescription), its brand-only status (no generic rifaximin 550mg is available in the U.S.), and its placement on specialty tiers (Tier 5 on most formularies). From the payer’s perspective, a $2,200 per-fill medication with no generic alternative warrants verification that the patient meets clinical criteria before the plan covers it.
Understanding the Insurance Company's Perspective
Payers require PA for Xifaxan because of three factors: the drug’s high cost (over $2,200 retail per prescription), its brand-only status (no generic rifaximin 550mg is available in the U.S.), and its placement on specialty tiers (Tier 5 on most formularies). From the payer’s perspective, a $2,200 per-fill medication with no generic alternative warrants verification that the patient meets clinical criteria before the plan covers it.
Payer concerns center on ensuring appropriate use for FDA-approved indications only, enforcing step therapy to verify that less expensive GI medications were tried first, and applying quantity limits to prevent off-label overuse. For IBS-D, most plans limit Xifaxan to 14-day courses and require a new PA for repeat treatment cycles. For hepatic encephalopathy, ongoing use is typically approved with periodic reauthorization showing continued clinical benefit.
For your practice, this means the PA is not optional, and incomplete submissions are the number one reason Xifaxan PAs get denied. Payers are not trying to block the drug. They are verifying clinical appropriateness for a high-cost specialty medication. 97% of commercially insured patients have Xifaxan coverage available, but most plans require PA documentation before dispensing (Salix Pharmaceuticals).
Why Prior Authorization for Xifaxan?
Xifaxan has three FDA-approved indications, and each one triggers different PA criteria from payers.
Hepatic encephalopathy (HE) is the most commonly approved indication. Xifaxan is FDA-approved for reduction in risk of overt HE recurrence in adults. Most payers require documentation of concurrent lactulose therapy, liver function labs, and evidence of prior HE episodes before they will approve ongoing Xifaxan coverage. For HE, authorization periods are typically 6-12 months with reauthorization required showing continued clinical need.
IBS-D (irritable bowel syndrome with diarrhea) is the second major indication. Payers require documentation of Rome IV criteria (recurrent abdominal pain associated with defecation, change in stool frequency, and change in stool form) and trial/failure of at least one alternative therapy. The IBS-D course is typically 14 days (550mg three times daily), and many plans require a new PA for each repeat course, which creates a recurring administrative burden for patients who need multiple treatment cycles.
Traveler’s diarrhea is the third FDA-approved indication, covering treatment of diarrhea caused by noninvasive E. coli strains in patients 12 and older. This is a less common PA trigger but still required by some plans.
Step therapy is the dominant PA barrier across all three indications. Payers want documentation that less expensive GI medications were tried first. Quantity limits add another layer, with many plans capping day supply or number of refills. Off-label use for SIBO or Crohn’s may be covered through a formulary exception with a letter of medical necessity, but the criteria are stricter and the approval rate is lower.
The recurring PA burden for IBS-D patients deserves specific attention. Unlike hepatic encephalopathy, where Xifaxan is typically approved for ongoing use, IBS-D treatment is structured as 14-day courses. Patients who respond to the first course but relapse (which happens in 40-50% of cases based on clinical trial data) need a new PA for each repeat course. A GI practice managing 30 active IBS-D patients on Xifaxan may process 15-20 repeat-course PAs per quarter, each requiring updated documentation showing symptom recurrence and continued Rome IV criteria. Without a dedicated PA workflow for repeat Xifaxan courses, these submissions stack up and delay treatment for patients who have already proven they respond to the medication.
Step-by-Step Guide to Securing Prior Authorization for Xifaxan
Step 1: Verify formulary status and payer-specific requirements. Before prescribing, check the patient’s plan formulary for Xifaxan tier status and PA requirements. Identify whether the plan requires step therapy, quantity limits, or a specific PA form. Use CoverMyMeds or the payer’s electronic portal to determine the exact criteria. This verification takes 5-10 minutes and prevents wasted time submitting documentation that does not meet the plan’s specific requirements.
Step 2: Gather clinical documentation. Collect the confirmed diagnosis with the appropriate ICD-10 code. For hepatic encephalopathy, gather documentation of prior HE episodes, confirmation of current lactulose therapy, and liver function labs (albumin, bilirubin, ammonia levels). For IBS-D, document that the patient meets Rome IV criteria and include trial and failure of alternative therapies with specific dates, doses, duration of each trial, and reasons for failure. For traveler’s diarrhea, include stool culture results confirming noninvasive E. coli. Vague documentation such as “tried other medications” will be denied. Include specific details for each prior medication: “Patient took dicyclomine 20mg QID for 6 weeks (January through February 2026) with no reduction in diarrhea frequency per patient diary.”
Step 3: Complete the PA submission. Use the payer’s preferred submission method. Electronic portal submission through CoverMyMeds or the payer’s direct portal is faster than fax and creates an automatic audit trail. Include a letter of medical necessity with clinical justification tied to FDA labeling and clinical guidelines. Attach supporting documentation: progress notes, lab results, and medication history. Submit proactively at the time of prescribing rather than waiting for a pharmacy rejection, which adds 1-3 days to the timeline.
Step 4: Track and follow up. Under CMS-0057-F (effective January 2026), payers must respond within 72 hours for urgent requests and 7 calendar days for standard requests. If no response arrives within the required timeframe, escalate immediately by calling the payer’s PA department with your reference number. Document all communication with the payer including dates, reference numbers, and representative names. This documentation is essential if the case progresses to appeal.
Step 5: Handle denials. Review the specific denial reason, which is now required under CMS-0057-F. Common denial reasons include incomplete documentation, step therapy not met, quantity limit exceeded, and off-label indication. Resubmit with the missing documentation or request a peer-to-peer review with the payer’s medical director. The AMA reports that 81.7% of PA denials are fully or partially overturned on appeal. Do not accept the first denial as final.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
ICD and CPT Codes Explained
Correct coding is essential for Xifaxan PA approval. The ICD-10 code must match the specific FDA-approved indication, and a mismatch between the diagnosis code and the requested dosing regimen triggers an automatic denial.
The primary ICD-10 codes for Xifaxan PA are: K72.90 for hepatic failure, unspecified without coma (the most common HE code), K72.91 for hepatic failure with coma, K76.7 for hepatorenal syndrome (used as supporting documentation alongside the primary HE code), K58.0 for irritable bowel syndrome with diarrhea, and A04.4 for other intestinal E. coli infections (traveler’s diarrhea).
Xifaxan is typically covered under the pharmacy benefit rather than the medical benefit, so CPT codes are rarely required for the PA submission. In cases where Xifaxan is administered in an inpatient setting, use the appropriate E&M codes for the encounter rather than a drug-specific CPT code.
The NDC numbers are 65649-0103-02 for Xifaxan 550mg (60-tablet pack) and 65649-0301-03 for Xifaxan 200mg. Always match the ICD-10 code to the specific FDA-approved indication. Submitting K58.0 (IBS-D) but requesting HE dosing (550mg three times daily on an ongoing basis) will trigger a mismatch denial because the dosing regimen does not match the indication represented by the diagnosis code.
For hepatic encephalopathy cases, include supporting codes for the underlying liver condition (K74.x for fibrosis/cirrhosis, K70.x for alcoholic liver disease) alongside the primary K72.90 code. The supporting codes strengthen the medical necessity argument and help payer reviewers understand the full clinical picture without requiring additional documentation requests. For IBS-D patients who have tried and failed multiple therapies, listing each failed medication with its ICD-10 code for the adverse effect or treatment failure provides a cleaner clinical narrative than relying solely on the letter of medical necessity.
Xifaxan Coverage by Payer Type
Commercial insurance. 97% of commercially insured patients have Xifaxan coverage available through their plan (Salix Pharmaceuticals). The drug typically sits at Tier 5 (specialty tier) with copays around 30% of the retail cost, which can mean $600 or more per fill for patients without copay assistance. A copay savings card is available from Salix that reduces the patient cost to $10 or less per prescription for eligible commercially insured patients. PA is required by most major commercial plans including UHC, Cigna, Aetna, and BCBS. Coverage criteria and step therapy requirements vary by payer.
Medicare Part D. 100% of Medicare Part D plans cover Xifaxan, though PA is still required. Coverage falls under the Part D pharmacy benefit, not Part B medical benefit. Standard PA criteria apply, with coverage requirements similar to commercial plans. Given the drug’s high cost, donut hole and catastrophic phase cost-sharing are significant considerations for Medicare patients. Once a patient hits the coverage gap, out-of-pocket costs increase substantially until catastrophic coverage kicks in. For hepatic encephalopathy patients on continuous Xifaxan therapy, the annual drug cost alone can push patients into the catastrophic phase within the first few months of the plan year. Practices should discuss cost trajectory with Medicare patients at the time of prescribing and consider referral to Medicare SHIP counseling for plan improvement during open enrollment. The Inflation Reduction Act’s $2,000 annual out-of-pocket cap for Part D (effective 2025) provides meaningful protection for these patients, but the PA requirement remains regardless of cost-sharing status.
Medicaid. Bausch Health/Salix exited the Medicaid drug rebate program and 340B pricing program effective October 1, 2025. This is a critical change that affects Medicaid Xifaxan coverage nationwide. State Medicaid programs may have dropped Xifaxan from their formularies or imposed stricter PA criteria following the rebate withdrawal. For Medicaid patients who have lost coverage, the Xifaxan Patient Assistance Program is available at bauschhealthpap.com or by calling 1-833-862-8727. State-specific Medicaid coverage details for FL, TX, and OH are covered in the section below.
State-Specific Xifaxan Coverage (Florida, Texas, Ohio)
Florida. Florida Medicaid (managed through Staywell, Sunshine Health, Molina, and other MCOs) included Xifaxan on the Preferred Drug List (PDL) with PA for HE and IBS-D indications. After the Bausch Health rebate withdrawal, verify current PDL status through the AHCA website before submitting. Florida commercial plans (Florida Blue, Humana FL, Aetna Better Health FL) follow national payer criteria with PA required for all Xifaxan prescriptions.
Texas. Texas Medicaid uses the Vendor Drug Program (VDP) PDL. Xifaxan’s status on the Texas PDL should be verified at txvendordrug.com following the rebate withdrawal. Texas commercial plans and Medicare Advantage plans follow national payer criteria. The Texas Medical Records Privacy Act (HB 300) requires annual HIPAA training for all PA staff handling patient records.
Ohio. Ohio Medicaid (administered through CareSource, Molina, Buckeye, and other MCOs) applies separate PA criteria by MCO. Verify the patient’s specific MCO formulary rather than relying on a statewide PDL. Each Ohio MCO manages its own formulary independently, so a drug that is preferred on CareSource’s list may require step therapy under Molina or be non-formulary with Buckeye. Ohio HB 668 safe harbor provisions may reduce liability for practices that maintain documented cybersecurity frameworks when handling PA submissions containing PHI. For practices serving multiple Ohio MCOs, maintaining a payer-specific Xifaxan reference sheet with each MCO’s current formulary status, PA criteria, and preferred submission method prevents the repeated research that wastes staff time on every new Xifaxan PA.
Post-Bausch Health Rebate Withdrawal Impact Across All Three States The October 2025 withdrawal of Bausch Health/Salix from the Medicaid Drug Rebate Program affected Xifaxan access for Medicaid patients in all 50 states, but the operational impact varies by state. In Florida, the MCOs had advance notice and some arranged alternative rebate structures directly with Bausch Health. In Texas, the VDP formulary committee reviewed Xifaxan’s PDL status in Q4 2025 and practices should verify the current listing before every Medicaid submission. In Ohio, each MCO made independent formulary decisions, meaning Xifaxan may be covered under one Ohio MCO and not another within the same county. For Medicaid patients who lost Xifaxan coverage due to the rebate withdrawal, the Xifaxan Patient Assistance Program through Bausch Health provides free medication to qualifying patients. The enrollment process requires a completed application form, proof of Medicaid coverage, and a signed prescription from the treating provider. Processing takes 5-10 business days after complete application receipt.
Common Xifaxan PA Denial Reasons and How to Appeal
The top five denial reasons for Xifaxan PA are: (1) incomplete documentation, (2) step therapy not met, (3) quantity limit exceeded, (4) off-label indication (such as SIBO or Crohn’s), and (5) a mismatch between the diagnosis code and the requested dosing regimen. To appeal, review the specific denial reason now required under CMS-0057-F, resubmit with the missing documentation, or request a peer-to-peer review with the payer’s medical director. The AMA reports that 81.7% of PA denials are fully or partially overturned on appeal, so do not accept the first denial as final.
Prior authorization requirements continue to increase across all payer types. The AMA’s 2024 Prior Authorization Physician Survey found that physicians complete an average of 43 PA requests per week, with each request consuming significant staff time. For practices handling specialty medications, imaging studies, or surgical procedures, the PA workload can consume 12 or more staff hours per week. That is time pulled directly from patient care activities and revenue-generating tasks.
The financial impact goes beyond staff time. Delayed authorizations mean delayed treatment, which affects patient satisfaction scores and can trigger downstream complications that cost more to treat. Practices report that PA-related delays contribute to appointment cancellations, no-shows, and patient attrition to competitors who can get approvals faster. When a patient waits two weeks for an authorization that should have taken three days, the practice relationship suffers regardless of whether the delay was the payer’s fault or the staff’s.
The denial rate for prior authorizations adds another layer of cost. When a PA request is denied, staff must research the reason, gather additional documentation, schedule peer-to-peer reviews with payer medical directors, and file formal appeals. Each denied PA represents 3-5 additional hours of staff work beyond the initial submission. Multiply that across dozens of denials per month and the cost becomes unsustainable for many practices.
Outsourcing PA to a dedicated team with payer-specific expertise addresses both the time and quality problems, especially for a high-volume GI drug like Xifaxan. Staffingly’s gastroenterology prior authorization specialists handle the full authorization lifecycle from initial submission through peer-to-peer reviews and formal appeals. Working across 50+ EHR platforms and serving 800+ providers, Staffingly goes live within 48-72 hours at $399/week (volume discounts to $299/week) with a 99.2% clean claim rate. The 15-Day Risk-Free Pilot lets practices test the service with zero upfront cost and no long-term contract required.
